Paley Jeffrey
Known title: DirectorCIK: 0001595327
Paley Jeffrey's purchase track record
Paley Jeffrey has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/6/2023 | DERM | $45K | +74.7% | +27.3% | +20.8% |
| 9/21/2023 | DERM | $89K | +165.7% | +28.6% | +21.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DERM | ▼ Sell | Open Market | 1,745 | $9K | 11/28/2023 | View on chart |
| DERM | ▼ Sell | Open Market | 255 | $959 | 11/8/2023 | View on chart |
| DERM | ▼ Sell | Open Market | 2,245 | $8K | 11/7/2023 | View on chart |
| DERM | ▲ Buy | Open Market | 15,000 | $45K | 10/6/2023 | View on chart |
| DERM | ▲ Buy | Open Market | 30,000 | $89K | 9/21/2023 | View on chart |
| DERM | ▲ Buy | Grant | 27,472 | $0 | 7/21/2023 | View on chart |
| DERM | ▲ Buy | Grant | 14,245 | $0 | 7/21/2022 | View on chart |
| DERM | ▲ Buy | Grant | 30,000 | $0 | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Options Activity Signals Possible Move in Journey Medical (DERM)
Options traders are increasing positions in Journey Medical, hinting at a potential price move. The stock is near its 9‑touch support level of $6.05 and has recently touched the 200‑day SMA, adding to the technical backdrop. Analysts currently target a range of $13.00 to $15.00, well above the 52‑week high of $9.55.
Options Activity Signals Possible Move in Journey Medical (DERM). Options traders are increasing positions in Journey Medical, hinting at a potential price move. The stock is near its 9‑touch support level of $6.05 and has recently touched the 200‑day SMA, adding to the technical backdrop. Analysts currently target a range of $13.00 to $15.00, well above the 52‑week high of $9.55.